Medical Oncologist
Medicines
How much does fulvestrant actually help? The numbers explained
Fulvestrant keeps hormone receptor positive advanced breast cancer controlled for months to years, with the longest benefit when the cancer has not yet met hormone treatment or when a targeted tablet is added. This page explains the key trials in plain language, what medians really mean and how to use the figures in conversations with your oncologist.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- What the trials show about how much fulvestrant helps
- Understanding the numbers in trials
- Approximate median time before the cancer grew
- The vocabulary, in plain language
- Honest realities about these numbers
- What is known about overall survival
- How to talk about benefit with your oncologist
- What people assume about fulvestrant results
- Common questions about how much fulvestrant helps
The short answer
What the trials show about how much fulvestrant helps
Fulvestrant is used for hormone receptor positive, HER2-negative breast cancer that has spread or come back. Its benefit is measured mainly by how long it keeps the cancer from growing, called progression-free survival, and sometimes by how long people live overall. Trials usually report the median, the point at which half the people in a group had their cancer grow and half had not. That makes averages useful for comparing treatments, but not for predicting any one person's course. On its own, fulvestrant helps most in cancers that have not yet met hormone treatment. In the FALCON trial, among such women, the median time before the cancer grew was about sixteen and a half months with fulvestrant compared with about fourteen months with anastrozole, and the gap was larger when the cancer had not spread to the liver or lungs. After earlier hormone treatment, fulvestrant alone controls the cancer for a shorter time, often around six months on average. The biggest gains come from combining fulvestrant with a targeted tablet. In the MONALEESA-three and MONARCH-two trials, adding ribociclib or abemaciclib roughly added several months of cancer control and also helped people live longer on average. For cancers with specific gene changes, alpelisib or capivasertib added to fulvestrant also lengthened control of the cancer.
Medians describe groups
Half of people do better than the median and half do worse, sometimes by a wide margin.
Earlier use tends to help more
Cancers that have not become resistant to hormone treatment usually respond for longer.
Combinations add the most
Pairing fulvestrant with a suitable targeted tablet has produced the largest improvements.
This page gives general information only. Trial figures are approximate and cannot predict your own outcome.How benefit is measured
Understanding the numbers in trials
A few terms unlock most of what trial reports say.
Progression-free survival
How long the cancer stays controlled without growing or spreading, measured mainly by scans.
Overall survival
How long people live from the start of treatment, whatever later treatments they receive.
Harder to show, because many treatments follow.The median
The middle value: half of people had the event sooner and half later.
Hazard ratio
A comparison of risk between two groups over time.
Things to keep in mind
- Trials include selected, often fitter patients
- Treatments after the trial differ
- Newer options may have changed outcomes
Key trials
Approximate median time before the cancer grew
Trial and setting
Median cancer control, roughly
FALCON: no earlier hormone treatment, fulvestrant or anastrozole
About sixteen and a half months versus about fourteen months
CONFIRM: after earlier hormone treatment, current dose or lower dose
About six and a half months versus about five and a half months
MONALEESA-three: fulvestrant with ribociclib or alone
About twenty and a half months versus about thirteen months
MONARCH-two: fulvestrant with abemaciclib or alone, after hormone treatment
About sixteen months versus about nine months
PALOMA-three: fulvestrant with palbociclib or alone, after hormone treatment
About nine and a half months versus about four and a half months
Words you will hear
The vocabulary, in plain language
- Endocrine-naive
- A cancer that has not been treated with hormone treatment before.
- Randomised trial
- A study where people are assigned treatments by chance, to compare them fairly.
- Placebo
- A dummy treatment used for comparison in some trials.
- Response rate
- The share of people whose cancer shrank by a set amount on scans.
- Clinical benefit
- Cancer that shrank or stayed stable for a meaningful length of time.
- Subgroup
- A smaller group within a trial, such as people without liver or lung spread.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
Honest realities about these numbers
Numbers can reassure and frighten at the same time. It helps to know what they can and cannot say.
Trial patients are not everyone
People in trials were usually fitter, with fewer other illnesses, than many people treated in everyday clinics.
Treatment has moved on
Some trials were run before CDK4/6 inhibitors became standard first treatment, so their figures may not match today's situations.
Averages hide long responders
A small but real group of people stay on fulvestrant-based treatment for many years.
What this page cannot tell you
It cannot tell you how long fulvestrant will work for you. Your oncologist can put figures into context.
Living longer
What is known about overall survival
Showing that a treatment helps people live longer takes large trials and long follow-up.
The current dose
In CONFIRM, the dose used today helped people live a few months longer on average than an older, lower dose.
With ribociclib or abemaciclib
In MONALEESA-three, median overall survival was about fifty-four months with ribociclib added versus about forty-one and a half months without. In MONARCH-two, it was about forty-seven months with abemaciclib versus about thirty-seven months.
With palbociclib
PALOMA-three showed a longer average survival of several months, though the result did not reach firm statistical certainty.
With gene-targeted tablets
For alpelisib and capivasertib, the main proven benefit is longer cancer control in selected cancers.
Using the numbers
How to talk about benefit with your oncologist
Trial figures become more useful when they are linked to your own situation.
Ask about people like you
Ask how your earlier treatment, where the cancer is and your test results compare with the trials.
Ask about the trade-offs
Adding a tablet may add months of control but also more side effects, tests and cost.
Ask what matters to you
Quality of life, fewer hospital visits and time with family are valid priorities alongside length of control.
Commonly believed
What people assume about fulvestrant results
The median is how long I have.
It describes a group, and many people do far better than the median.
Fulvestrant alone is as good as a combination.
Adding a suitable targeted tablet generally lengthens cancer control.
If it helps for a few months, it has failed.
Every period of control counts, and other treatments usually follow.
Trial numbers apply exactly to Indian patients.
Trials give a guide, but local factors and individual health can change outcomes.
Questions we are asked
Common questions about how much fulvestrant helps
What does progression-free survival actually mean for me?
It is the length of time the cancer stays under control before scans show growth. It does not mean the end of treatment options. When the cancer grows, a new treatment is usually started, and many people go on to benefit from several treatments in turn.
Does fulvestrant shrink tumours?
Sometimes. In many people the main benefit is keeping the cancer stable rather than making it shrink. Stable disease that lasts a long time is a good result, and trials count it as clinical benefit alongside shrinkage.
Why is the benefit smaller after earlier hormone treatment?
Cancers adapt to treatments. After time on tamoxifen or aromatase inhibitors, some cancer cells find other ways to grow, so any hormone treatment tends to work for a shorter time. Adding a targeted tablet can help overcome some of this resistance.
Was the old lower dose less effective?
Yes. The CONFIRM trial showed the higher dose used today controlled the cancer for longer and helped people live longer than the older, lower dose. That is why the current schedule, including the extra early dose, is recommended.
Does it matter if the cancer is in my bones only?
Cancers limited to bone or lymph nodes often respond to hormone treatment for longer than cancers in the liver or lungs. In FALCON, the advantage of fulvestrant over anastrozole was clearest in people without liver or lung spread.
Are Indian patients likely to see the same results?
The biology of hormone receptor positive breast cancer is broadly similar worldwide. However, factors such as stage at diagnosis, access to tests, cost-related gaps in treatment and other illnesses can affect results. Regular treatment and follow-up help.
Should I choose the combination for the bigger numbers?
For many people, the combination is recommended because the benefit is meaningful. But it adds side effects, blood tests and cost. Discuss your health, preferences and practical situation with your oncologist to reach a choice that suits you.
Where do these figures come from?
They come from large published randomised trials, reported in medical journals. Figures here are rounded for readability. Your oncologist can explain the full results and how newer studies may have updated them.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- The Lancet — Fulvestrant versus anastrozole for hormone receptor-positive advanced breast cancer (FALCON)
- New England Journal of Medicine — Overall survival with ribociclib plus fulvestrant in advanced breast cancer
- JAMA Oncology — Effect of abemaciclib plus fulvestrant on overall survival (MONARCH 2)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.